Placebo News and Research

RSS

Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

The Pan Am Cancer Treatment Center is pleased to announce the publication of a specialized textbook titled "Immuno-Oncology, from Bench to Bedside" which provides scientific rationale for the use of immunotherapy in the treatment of cancer.

25 Jun 2015

Researchers determine underlying barriers to carrying out effective clinical trials in Parkinson's disease

Despite an urgent need for new medications, clinical trials in Parkinson's disease (PD) have a relatively low rate of success.

25 Jun 2015

Study sheds new light on role of patient-doctor relationship in antidepressant drug treatment

A study published in the current issue of Psychotherapy and Psychosomatic sheds new light on the role of patient-doctor relationship in antidepressant drug treatment.

24 Jun 2015

Research shows New Zealand blackcurrants are good for keeping us mentally young and agile

Research has shown that New Zealand blackcurrants are good for keeping us mentally young and agile, a finding that could have potential in managing the mental decline associated with aging populations, or helping people with brain disorders such as Parkinson's disease or depression.

24 Jun 2015

Study analyzes effects of inhaled cannabis on driving performance

A new study conducted at the University of Iowa's National Advanced Driving Simulator has found drivers who use alcohol and marijuana together weave more on a virtual roadway than drivers who use either substance independently.

24 Jun 2015

Johns Hopkins scientists use experimental therapy to reverse progression of atherosclerosis in rodents

In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals’ ability to properly handle cholesterol.

24 Jun 2015

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.

24 Jun 2015

Promoting healthy foods to children

If the packaging has an appealing design, primary school children also reach for healthy foods. This was revealed in a study in cooperation with the Research Institute for Child Nutrition in Dortmund under the direction of scientists from the University of Bonn. The results are being published in advance online in the journal Frontiers in Psychology. The final version will be published shortly.

23 Jun 2015

Statins benefit patients undergoing major lung resection, lower major complications

Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery.

23 Jun 2015

Atrial fibrillation patients who stop blood thinners before elective surgery have less risk of major bleeding

Patients with atrial fibrillation who stopped taking blood thinners before they had elective surgery had no higher risk of developing blood clots and less risk of major bleeding compared to patients who were given a "bridge" therapy, according to research led by Duke Medicine.

23 Jun 2015

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy.

22 Jun 2015

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.

22 Jun 2015

Finding may pave way for much-needed treatments for people with epilepsy

An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins.

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis.

19 Jun 2015

Human breast milk bought online poses serious health risks

The recent craze for human breast milk, which has become a lucrative online market, poses serious health risks, according to British experts.

19 Jun 2015

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.

19 Jun 2015

Injectable drug ocriplasmin improves vision in patients with symptomatic vitreomacular adhesion

In two ancillary studies of two multi-center international clinical trials led by the University of Southern California Eye Institute, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion (VMA), a condition related to the aging eye that could cause permanent vision loss if left untreated.

18 Jun 2015

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine.

17 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Placebo News and Research

Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

Researchers determine underlying barriers to carrying out effective clinical trials in Parkinson's disease

Study sheds new light on role of patient-doctor relationship in antidepressant drug treatment

Research shows New Zealand blackcurrants are good for keeping us mentally young and agile

Study analyzes effects of inhaled cannabis on driving performance

Johns Hopkins scientists use experimental therapy to reverse progression of atherosclerosis in rodents

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Promoting healthy foods to children

Statins benefit patients undergoing major lung resection, lower major complications

Atrial fibrillation patients who stop blood thinners before elective surgery have less risk of major bleeding

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Opioid offers pain relief for Parkinson’s patients

Finding may pave way for much-needed treatments for people with epilepsy

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

Human breast milk bought online poses serious health risks

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Injectable drug ocriplasmin improves vision in patients with symptomatic vitreomacular adhesion

CGRP monoclonal antibodies show promise in treating migraine

Novartis presents positive Phase III results of Farydak therapy at EHA

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News